China as an Innovator in Finished Dosage Formulations: From Generics to Cutting-Edge Therapies

Published 1 September 2025 in Innovation & Technology.

This article is kept with its original date and commentary. Market figures, forecasts and regulatory references reflect the time of writing and were not re-verified.

China transitions from generics leader to innovation hub, contributing ~30% to global R&D pipeline.

Rapid advancements in high-end FDF reflect policy and investment shifts.

Innovation Highlights

Biosimilars Boom: Numerous mAb biosimilars launched, expanding sterile capabilities.
Complex Generics: Progress in controlled-release and specialty products via consistency evaluations.
Novel Therapies: ADCs, GLP-1 analogs, and advanced injectables through collaborations.
Policy Support: Reforms encourage differentiation and global competitiveness.

China's innovators deliver affordable advanced FDF therapies worldwide.

Bring the conversation to your own product.

Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.

Prepare a sourcing enquiry Discuss regulatory or CDMO support

Telephone+98 21 8888 3325 · office hours 09:00–17:00, Tehran

OfficeHaniya Parsan Darou, 3rd floor, No. 326, Zafar Street, Africa Boulevard, Tehran 1968734974, Iran

Emailcontact@hanpars.com